E for L Aim PCL
SET:EFORL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
E for L Aim PCL
SET:EFORL
|
TH |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
G
|
Grupo Media Capital SGPS SA
ELI:MCP
|
PT |
|
Plaza Indonesia Realty Tbk PT
IDX:PLIN
|
ID |
|
H
|
Humana Inc
F:HUM
|
US |
|
Link Net Tbk PT
IDX:LINK
|
ID |
|
M
|
Merck & Co Inc
BMV:MRK
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is EFORL's stock price target?
Not Available
EFORL does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for E for L Aim PCL?
Projected CAGR
14%
Over the last 13 years, the compound annual growth rate for Revenue has been 24%. The projected CAGR for the next 10 years is 14%.
What is the Operating Income forecast for E for L Aim PCL?
Projected CAGR
25%
The compound annual growth rate for Operating Income over the next 10 years is 25%.
What is the Pre-Tax Income forecast for E for L Aim PCL?
Projected CAGR
26%
The compound annual growth rate for Pre-Tax Income over the next 10 years is 26%.
What is the Net Income forecast for E for L Aim PCL?
Projected CAGR
23%
The compound annual growth rate for Net Income over the next 9 years is 23%.
